Clinical trial · Interventional
Allogeneic CART-33 for Relapsed/Refractory CD33+ AML
Treatment of Relapsed and/or Refractory CD33-positive Acute Myeloid Leukemia by Infusions of Allogeneic CART-33
NCT02799680CI-TRIAL-00022598unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 33 (CD33)-directed chimeric antigen receptor modified T cells (CART-33) infusions in patients with relapsed / refractory acute myeloid leukemia (AML).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed and/or Refractory CD33+ AML | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| allogeneic CART-33 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- allogeneic CART-33
- description
- infusions of allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
- interventionNames
- Biological: allogeneic CART-33
Primary outcomes (1)
- measure
- Occurrence of study related adverse events
- timeFrame
- 1 year
- description
- defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria
Secondary outcomes (3)
- measure
- Overall response rate of allogeneic CART-33
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 50 years * Patient with relapsed and/or refractory CD33 positive acute myeloid leukemia (AML) * Estimated life expectancy ≥ 12 weeks (according to investigator's judgment) * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Exclusion Criteria: * Previous treatment with investigational gene or cell therapy medicine products * CD33 negative leukemia * Any uncontrolled active medical disorder that would preclude participation as outlined * Pregnant or lactating women
References
Publications (0)
Data not yet available
No reference posted for this study.